mL (sole generic) approval did nothing for the stock... why should we expect mC approval to be any different.
That's surely not how I remember "approval." The stock went nuts (originally). Then, the market started focusing on the economics of the NVS arrangement and the likelihood of tL approval.
A mC approval will not have the economic problems of mL- but it may have a significant delay if MNTA/NVS does not prevail in the patent case. But the numbers will just be too big not to have some market effect (though maybe not as much as many here - include me - hope). The market will eventually recognize value. Many are too impatient. Plus there are no guarantees in life (e.g. a new treatment may take away the Cop market).
Market Data 
Markets 
